CalciMedica, Inc. Common Stock (CALC)vsMerck & Company Inc (MRK)
CALC
CalciMedica, Inc. Common Stock
$0.64
-3.70%
HEALTHCARE · Cap: $11.71M
MRK
Merck & Company Inc
$135.17
-0.59%
HEALTHCARE · Cap: $335.46B
Smart Verdict
WallStSmart Research — data-driven comparison
MRK leads profitability with a 4.8% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 34/100 (F).
CALC
Avoid19
out of 100
Grade: F
MRK
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CALC.
Margin of Safety
-64.9%
Fair Value
$82.46
Current Price
$135.17
$52.71 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CALC
CALC has a balanced fundamental profile.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : CALC
The primary concerns for CALC are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRK
The primary concerns for MRK are Return on Equity, Profit Margin, Debt/Equity. A P/E of 108.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
CALC carries more volatility with a beta of 1.12 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (34/100 vs 19/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CalciMedica, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
CalciMedica, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative therapies that target calcium-dependent pathways to address both acute and chronic health challenges. The company’s lead candidate, CM4620, aims to alleviate severe muscle cramps associated with sickle cell disease, underscoring its focus on meeting critical unmet medical needs. With a robust proprietary technology platform and an expanding pipeline of novel calcium modulators, CalciMedica is well-positioned for significant growth. Backed by an experienced management team and key strategic partnerships, the company presents a compelling investment opportunity within the biopharmaceutical sector.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?